TIL Therapy Market Revenue to Cross USD 2.5 billion by 2035 | Roots Analysis

Published: February 2023

According to a recently published report by Roots Analysis, the growing development pipeline and encouraging clinical trial results is driving the TIL therapy market growth

TIL Therapy Market Industry Overview

The global TIL therapy market is anticipated to grow at a CAGR of 40% from 2023-2035, reaching USD 5 billion by 2035.

Tumor infiltrating lymphocytes (TILs) constitute a diverse group of mononuclear lymphocytes, encompassing T-cells, B-cells, NK cells, and macrophages isolated from the tumor environment. Therapies utilizing TILs involve the retrieval of these cells from tumor specimens, followed by in vitro expansion with the aid of IL-2, a growth factor. The expanded autologous TILs are subsequently reintroduced into the respective cancer patients. Once in the host, these cells play a crucial role in eliminating tumor cells, and their capacity to form a memory response allows them to target recurring tumors. Importantly, such therapies often do not necessitate special interventions to maintain immunological memory persistence.

Browse 120+ figures and 135+ market data tables spread across 285+ pages and detailed Table of Content on “ TIL Therapy Market by Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/til-therapies-market.html

Market Drivers

Several factors are propelling the growth of the TIL therapy market. The increasing prevalence of cancer cases is driving the demand for tumor infiltrating lymphocyte therapies / TIL therapies, consequently propelling market growth. Further, the ongoing and planned clinical research initiatives in this domain are driven by encouraging results achieved in past trials, which were mostly focused on various solid tumors. Additionally, owing to the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the demand for TIL therapies is also expected to witness a significant rise.

Market Restraints

While the TIL therapy market is experiencing substantial growth, it is not without its challenges. One of the primary restraints is the high cost associated with the development of these therapies. This has led to an increase in the overall cost of TIL therapies and low patient adoption. Additionally, no TIL based therapy has yet been approved till now. These factors are expected to hinder the growth of this market in the coming years.

Growth Factors

Despite the challenges, several growth factors continue to drive the TIL therapy market forward. One notable factor is the polyclonal nature of these therapies which allows them to simultaneously recognize and attack more than one target. The chances of eliminating cells bearing tumor-specific antigens are high when TILs are used, thereby making the treatment more robust. Owing to their tumor-killing capability and therapeutic superiority, TIL therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders. Driven by several advantages and growth factors, TIL therapy market is likely to carve out a significant share of the multi billion-dollar cancer immunotherapy market.

TIL Therapy Market Segments

Based on the target indication, the market is segmented into Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia and Other Disorders.

  • The melanoma targeting TIL therapies are anticipated to lead the TIL therapy market, capturing the largest revenue share of more than 50.0% in 2035.
  • This is attributed to the fact that more than 40% of the TIL therapies are targeting melanoma and anticipated to show the highest growth potential during the forecast period of over 30% annually.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & North Africa

  • North America dominated the tumor infiltrating lymphocytes therapy market and accounted for the largest revenue share of about 50.0% in 2023.
  • In Asia Pacific, the tumor infiltrating lymphocytes therapy market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The TIL therapy market report also includes detailed profiles of key players (listed below) that develops tumor infiltrating lymphocytes therapies:

  • Cellectis
  • Cellular Biomedicine Group
  • Iovance Biotherapeutics
  • Lytix Biopharma
  • Phio Pharmaceuticals

Recent Developments in TIL therapy market

Several recent developments have taken place in the TIL therapy market. We have covered some of these recent initiatives below. These developments, even though they took place after the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In October 2023, Biosyngen announced the IND approval for its drug BST02 for patients suffering from liver cancer. This is worth highlighting that this will be the first ever TIL therapy which got IND approval for this indication till now.
  • In August 2023, Phio Pharmaceuticals in partnership with AgonOx and Providence Cancer Institute announced the dosing of first patient who is suffering from melanoma and other advanced solid tumors along with AGX148 'double positive' (DP) CD8 tumor-infiltrating lymphocytes (TIL) alone and in combination with Phio's PD-1 silencing PH-762.

You Can Download Free Sample PDF Copy of This Report At:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry